GlassScriptPhysician profile
Sandra K Charles
NPI 1093734436
$5,548.72
in general payments reported to CMS, 2019-2025
29 companies · $616 in 2025
The $616 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $840 · 2020: $575 · 2021: $824 · 2022: $717 · 2023: $998 · 2024: $978 · 2025: $616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,593.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,592.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $900.84 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $720.80 | 2019-2025 | Ubrelvy, Qulipta, Linzess |
| Glaxosmithkline, LLC. | $644.30 | 2019-2025 | Trelegy Ellipta, Bexsero, Shingrix |
| Lilly USA, LLC | $634.96 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Astrazeneca Pharmaceuticals LP | $460.67 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Janssen Pharmaceuticals, INC | $426.83 | 2019-2024 | Xarelto |
| Pfizer INC. | $349.45 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $211.20 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $167.37 | 2019-2023 | Eliquis |
| Merck Sharp & Dohme LLC | $123.86 | 2019-2025 | Gardasil 9, Capvaxive, Vaxelis |
| Phathom Pharmaceuticals, INC. | $119.30 | 2024-2025 | Voquezna |
| Amgen INC. | $113.05 | 2019-2025 | Otezla, Repatha |
| Amarin Pharma, INC. | $65.03 | 2020-2021 | |
| Braeburn INC. | $62.84 | 2024-2025 | Brixadi |
| Indivior INC. | $54.49 | 2024-2025 | Sublocade |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $54.37 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $53.73 | 2022 | |
| Biodelivery Sciences International, INC. | $49.75 | 2019-2020 | |
| Esperion Therapeutics, INC. | $46.42 | 2021-2024 | Nexletol |
| Sanofi-Aventis U.S. LLC | $44.19 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $41.64 | 2025 | Daybue |
| Biohaven Pharmaceutical Holding Company LTD. | $34.91 | 2022 | |
| Neurelis, INC. | $32.41 | 2022 | |
| Abbott Laboratories | $29.81 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.67 | 2019-2020 | |
| Exact Sciences Corporation | $24.74 | 2025 | The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $19.28 | 2023 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.58 | 2025 | Xifaxan |
| Biogen, INC. | $17.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Charles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.